Benign prostatic hyperplasia (BPH) affects ≈ 30 % of men ≥ 50 years and ≈ 70 % of men ≥ 80 years, imposing a $1.1 billion annual economic burden in the United States. The pathogenesis of BPH involves androgen‑driven stromal‑epithelial proliferation and dysregulated cyclic‑GMP signaling, which is… 📌 Key Points 📌 Overview and Epidemiology 📌 Pathophysiology 📌 Clinical Presentation ⏱ 7 min read 📖 Full article + sources: 🔗 https://medmind.pro/articles/tadalafil-in-the-management-of-benign-prostatic-hyperplasia-pharmacology-clinical-use-and- 📚 Free medical platform: medmind.pro #MedicalEducation #Medicine #MedMindAI #USMLE #MedStudent #Pharmacology
💊 Tadalafil in the Management of Benign Prostatic Hyperplasia: Pharmacology, Clinical Use, and Outcomes
Benign prostatic hyperplasia (BPH) affects ≈ 30 % of men ≥ 50 years and ≈ 70 % of men ≥ 80 years, imposing a $1.1 billion annual economic burden in the United States. The pathogenesis of BPH involves androgen‑driven stromal‑epithelial proliferation and dysregulated cyclic‑GMP signaling, which is…
📌 Key Points
📌 Overview and Epidemiology
📌 Pathophysiology
📌 Clinical Presentation
⏱ 7 min read
📖 Full article + sources:
📚 Free medical platform: medmind.pro
#MedicalEducation #Medicine #MedMindAI #USMLE #MedStudent
#Pharmacology
